Compare Core and Main Inc (CNM) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core and Main Inc vs Enveric Biosciences Inc — how do they compare? Core and Main Inc trades at $45.7 (market cap $8.73B), while Enveric Biosciences Inc trades at $1.56 (market cap $6.20M). The key difference: Core and Main Inc is far larger — about 1408.1× Enveric Biosciences Inc's market cap, and Core and Main Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| CNM | ENVB | |
|---|---|---|
Market Cap | $8.73B | $6.20M |
Sector | Technology | Health |
52-Week High | $66.98 | $17.40 |
52-Week Low | $42.37 | $1.27 |
Enterprise Value | $11.02B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core & Main (CNM) trades at $45.85, down 0.97% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings of $0.57 per share, beating estimates, and maintains solid fundamentals including a 23.73% ROE and 5.87% net margin. Recent news highlights institutional activity, such as California State Teachers Retirement System increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is positive with analyst consensus at 57% buy ratings, supported by revenue growth to $7.6B in 2026 and expanding margins. Risks include high debt levels at $2.24B long-term and competitive pressures in the tools sector. Investors should monitor execution against FY26 guidance of $7.8–$7.9B revenue.
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
